INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER

Clinical trials for INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER explained in plain language.

Never miss a new study

Get alerted when new INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER trials appear

Sign up with your email to follow new studies for INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug duo may zap bladder tumors without cutting

Disease control Not yet recruiting

This study tests two experimental treatments for people with intermediate-risk non-muscle invasive bladder cancer. The goal is to see if a drug called N-803, given with either BCG or gemcitabine directly into the bladder, can eliminate tumors without needing surgery. About 20 adu…

Matched conditions: INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER

Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control

Last updated Jun 17, 2026 04:54 UTC

INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER

Get alerted when new INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER trials appear

New drug duo may zap bladder tumors without cutting